AIBL III – Efficient identification of preclinical AD

https://neurodegenerationresearch.eu/survey/aibl-iii-efficient-identification-of-preclinical-ad/

Principal Investigators

Prof Christopher Rowe

Institution

Institute for Breathing and Sleep

Contact information of lead PI
Country

Australia

Title of project or programme

AIBL III - Efficient identification of preclinical AD

Source of funding information

National Health and Medical Research Council

Total sum awarded (Euro)

€ 490,392

Start date of award

01/01/2014

Total duration of award in years

4

Keywords
Research Abstract
Amyloid brain scans can detect the onset of Alzheimer's disease 10-15 years before symptoms first appear. Amyloid build-up is thought to be the cause of Alzheimer's disease. The earlier that drugs designed to slow the build up of amyloid or to clear it from the brain are given, the greater the chance of benefit. This study will use the recent discoveries from the Australian AIBL study to develop the best method to find these people with brain amyloid but no symptoms for early treatment trials to prevent dementia.

Further information available at:

Types:
Investments < €500k

Member States:
Australia

Diseases:
N/A

Years:
2016

Database Categories:
N/A

Database Tags:
N/A